> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bambusa Files For Nasdaq IPO With $41.1 Million Loss, No Revenue And A Going-Concern Warning
- URL: https://www.bullished.co/bambusa-files-for-nasdaq-ipo-with-41-1-million-loss-no-revenue-and-a-going-concern-warning-3a653ce5/
- Published: 2026-10-10T12:55:57.000Z
- Updated: 2026-10-10T12:55:57.000Z
- Description: The Boston antibody developer's S-1 leaves price and share count blank and says $71.5 million in cash may not last a year.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified

Bambusa Therapeutics, a Boston antibody developer, filed an [S-1 registration statement](https://www.sec.gov/Archives/edgar/data/0002044950/000162828026065557/bambusa-sx1.htm?ref=bullished.co) on Friday to list on the Nasdaq Global Select Market, and the document carries a going-concern warning. Management says there is "substantial doubt" the company can keep operating for the 12 months after its audited statements were available to be issued.

## The numbers behind the warning

The company has no products approved for sale and has reported no revenue. Its net loss was $41.1 million for 2025, against $13.7 million for the period from its March 2024 inception to the end of that year.

For the six months ended June 30, 2026, the net loss was $22.4 million, versus $14.7 million a year earlier. The accumulated deficit stood at $77.2 million.

Cash, cash equivalents and marketable securities totaled $71.5 million at June 30, 2026\. Private convertible preferred stock sales have raised $136.1 million in gross proceeds, from investors including ATHOS, BVF Partners, Dawn Biopharma (a KKR-controlled platform), INCE Capital, RA Capital and Salvia.

The filing says that even if the IPO succeeds, the company will need substantial additional capital, and that doubt about its survival could persist after the offering.

## What the offering terms say

The proposed symbol is BBTX. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are named on the cover.

The share count, price range and offering size are blank, so no terms have been set. The filing says the closing is contingent on the Nasdaq listing.

It also says the offering proceeds would go mainly to the lead drug, BBT001, including a planned mid-stage atopic dermatitis trial, and to the second drug, BBT002\. The dollar splits are blank.

As of June 30, 2026, 25,740,828 shares were outstanding after the preferred stock converts into 17,730,909 common shares at closing.

## The pipeline and its limits

BBT001 targets two pathways, IL-4Rα and IL-31, for atopic dermatitis, a skin disease. In a study of 17 patients with a June 8, 2026 data cutoff, the placebo-adjusted share reaching a 50% improvement in eczema severity (EASI-50) at Week 6 was 82%. For a 75% improvement (EASI-75) it was 64%.

The company expects more BBT001 readouts through the first half of 2027\. BBT002 targets IL-4Rα and IL-5, with COPD and nasal polyp readouts also expected in that period. Two preclinical candidates are planned to enter clinical trials by the end of 2026 and 2027.

The filing says the company's most advanced drugs are in early development and that early results may not predict later trials. It also discloses material weaknesses in its internal financial controls.

## The BioNTech connection

Bambusa was formed in March 2024 and acquired its lead candidates from BioNTech (Zhuhai) Pharmaceuticals R&D, a BioNTech subsidiary then known as Biotheus. CEO Shanshan Xu previously served as Head of Global External Innovations at BioNTech, and the filing says many employees also worked there.

The filing lists the risks of its dependence on third-party manufacturers, many of them sole-source, and on U.S.-China trade relations.

The filing will need an amendment that fills in the price range and share count before any pricing; none of those terms is set in the October 9 version.

### Sources

- [S-1 — Bambusa Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/0002044950/000162828026065557/bambusa-sx1.htm?ref=bullished.co) — SEC EDGAR